Chidamide in combination with chemotherapy in refractory and relapsed T lymphoblastic lymphoma/leukemia
| Autor: | Wei Guan, Yang Xiao, Yu Jing, Li Yu, Li-Ping Dou, Maoquan Wang |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Cancer Research
medicine.drug_class medicine.medical_treatment Salvage therapy Aminopyridines Hematopoietic stem cell transplantation 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Refractory hemic and lymphatic diseases Chidamide Antineoplastic Combined Chemotherapy Protocols medicine Humans Chemotherapy business.industry Lymphoma Non-Hodgkin Lymphoblastic lymphoma Histone deacetylase inhibitor hemic and immune systems Hematology Precursor Cell Lymphoblastic Leukemia-Lymphoma medicine.disease T-lymphoblastic lymphoma/leukemia Oncology chemistry 030220 oncology & carcinogenesis Benzamides Cancer research business 030215 immunology |
| Zdroj: | Leukemialymphoma. 61(4) |
| ISSN: | 1029-2403 |
| Popis: | Chidamide, a novel histone deacetylase inhibitor, has exerted effects in T-cell tumors through various mechanisms. Seventeen patients with refractory or relapsed T-cell acute lymphoblastic lymphoma/leukemia (T-LBL/ALL) received Chidamide combined with chemotherapy as salvage treatment. Historical data was analyzed as comparison as chemotherapy group. Complete response (CR) rate and overall response rate (ORR) of Chidamide + chemotherapy group were higher than that of chemotherapy group after one course. Chidamide + chemotherapy group had a better progress-free survival (PFS) compared to chemotherapy group. No difference in overall survival (OS) was observed. Grade 3/4 nonhematological adverse events (10%) of patients in Chidamide + chemotherapy group included febrile neutropenia (64.7%), drug-induced liver failure (17.6%), decreased fibrinogen (11.8%), sepsis (11.8%), pneumonitis (11.8%), and oral mucositis (11.8%). This study demonstrates that Chidamide included regimen may be a new treatment strategy with an acceptable safety profile for refractory or relapsed T-LBL/ALL patients but requires further investigation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|